Loading video...

Video Failed to Load

Go Home

𝐀𝐧𝐚𝐥𝐲𝐬𝐭 𝐓𝐡𝐮𝐫𝐬𝐝𝐚𝐲𝐬: Mizuho Senior Biotech Analyst Graig Suvannavejh shares his take on three key biotech trials that are scheduled to read out soon, and one that recently happened. $IDYA $EYPT $OCUL $PVLA $CRVS Full video:

BiotechTV's profile picture

BiotechTV

10,930 subscribers

29,397 views • 6 months ago •via X (Twitter)

LIVE

Anya Rossi• Live Now

Private livecam show

0 Comments

No comments available

Comments from the original post will appear here

Related Videos

𝐅𝐫𝐨𝐦 𝐍𝐘𝐒𝐄: Mizuho Senior Analyst Graig Suvannavejh shares his take on biotech and companies he covers that are in the news with key catalysts. $TERN $CRVS $INSM $CRBP $AXSM $NMRA $EYPT $AMLX Full video:
4:48

𝐅𝐫𝐨𝐦 𝐍𝐘𝐒𝐄: Mizuho Senior Analyst Graig Suvannavejh shares his take on biotech and companies he covers that are in the news with key catalysts. $TERN $CRVS $INSM $CRBP $AXSM $NMRA $EYPT $AMLX Full video:

BiotechTV

17,128 views • 8 months ago

𝐔.𝐒. 𝐒𝐜𝐢𝐞𝐧𝐜𝐞 𝐒𝐮𝐦𝐦𝐢𝐭: Alexis Borisy shares his take on one of today's biggest debates in biotech, the impact of China on the U.S. biotech sector.
4:15

𝐔.𝐒. 𝐒𝐜𝐢𝐞𝐧𝐜𝐞 𝐒𝐮𝐦𝐦𝐢𝐭: Alexis Borisy shares his take on one of today's biggest debates in biotech, the impact of China on the U.S. biotech sector.

BiotechTV

12,038 views • 1 month ago

𝐒𝐅 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐖𝐞𝐞𝐤: Perceptive Advisors' Joe Edelman, one of the top investors in biotech, shares his investment philosophy and his take on the sector heading into 2026. Full video:
3:49

𝐒𝐅 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐖𝐞𝐞𝐤: Perceptive Advisors' Joe Edelman, one of the top investors in biotech, shares his investment philosophy and his take on the sector heading into 2026. Full video:

BiotechTV

25,829 views • 7 months ago

𝐁𝐫𝐢𝐠𝐡𝐭 𝐌𝐢𝐧𝐝𝐬: William Blair Senior Biotech Analyst Andy Hsieh reacts to today's oral obesity data from Viking's VK2735 and recent data from Lilly's orforglipron. $VKTX $LLY Full video:
13:02

𝐁𝐫𝐢𝐠𝐡𝐭 𝐌𝐢𝐧𝐝𝐬: William Blair Senior Biotech Analyst Andy Hsieh reacts to today's oral obesity data from Viking's VK2735 and recent data from Lilly's orforglipron. $VKTX $LLY Full video:

BiotechTV

68,717 views • 1 year ago

𝐉𝐞𝐟𝐟𝐞𝐫𝐢𝐞𝐬 𝐋𝐨𝐧𝐝𝐨𝐧: Affinity Asset Advisors' Patrick Nosker shares a public investor's perspective on biotech and comments on a few of his firm's top positions. $XBI $XENE $MDGL $ALKS Full video:
4:30

𝐉𝐞𝐟𝐟𝐞𝐫𝐢𝐞𝐬 𝐋𝐨𝐧𝐝𝐨𝐧: Affinity Asset Advisors' Patrick Nosker shares a public investor's perspective on biotech and comments on a few of his firm's top positions. $XBI $XENE $MDGL $ALKS Full video:

BiotechTV

13,777 views • 9 months ago

𝐒𝐅 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐖𝐞𝐞𝐤: Perceptive Advisors' Joe Edelman, one of the top investors in biotech, shares his investment philosophy. See the whole interview here:
1:05

𝐒𝐅 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐖𝐞𝐞𝐤: Perceptive Advisors' Joe Edelman, one of the top investors in biotech, shares his investment philosophy. See the whole interview here:

BiotechTV

16,344 views • 7 months ago

𝐎𝐟𝐟-𝐓𝐚𝐫𝐠𝐞𝐭 𝐄𝐟𝐟𝐞𝐜𝐭𝐬: Matt Gline speaks with Avoro Capital's Behzad Aghazadeh about the hot button issues that have been striking the biotech sector. Full video:
7:13

𝐎𝐟𝐟-𝐓𝐚𝐫𝐠𝐞𝐭 𝐄𝐟𝐟𝐞𝐜𝐭𝐬: Matt Gline speaks with Avoro Capital's Behzad Aghazadeh about the hot button issues that have been striking the biotech sector. Full video:

BiotechTV

20,811 views • 1 year ago

𝐀𝐒𝐇 𝟐𝟎𝟐𝟒: Legend Biotech CEO Ying Huang on moving Carvykti into earlier settings, potential future competition, beyond BCMA, and more. #ASH24 $LEGN Full video:
0:48

𝐀𝐒𝐇 𝟐𝟎𝟐𝟒: Legend Biotech CEO Ying Huang on moving Carvykti into earlier settings, potential future competition, beyond BCMA, and more. #ASH24 $LEGN Full video:

BiotechTV

16,621 views • 1 year ago

𝐒𝐅 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐖𝐞𝐞𝐤: Abivax CEO Marc de Garidel reflects on a breakout 2025 for obefazimod and key data that will read out this year. $ABVX Full video:
3:51

𝐒𝐅 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐖𝐞𝐞𝐤: Abivax CEO Marc de Garidel reflects on a breakout 2025 for obefazimod and key data that will read out this year. $ABVX Full video:

BiotechTV

73,893 views • 7 months ago

From NYSE: Gameto CEO Dina Radenkovic / Turner talks about running a women's health biotech, the development of Fertilo, work on menopause, and more. Full video:
6:09

From NYSE: Gameto CEO Dina Radenkovic / Turner talks about running a women's health biotech, the development of Fertilo, work on menopause, and more. Full video:

BiotechTV

14,405 views • 1 year ago

𝐒𝐅 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐖𝐞𝐞𝐤: Meet some of the incredible Female Biotech CEO leaders of the Biotech CEO Sisterhood!
1:37

𝐒𝐅 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐖𝐞𝐞𝐤: Meet some of the incredible Female Biotech CEO leaders of the Biotech CEO Sisterhood!

BiotechTV

12,276 views • 7 months ago

𝐓𝐡𝐞 𝐒𝐭𝐮𝐝𝐢𝐨 𝐚𝐭 𝐊𝐞𝐧𝐝𝐚𝐥𝐥 𝐒𝐪𝐮𝐚𝐫𝐞: Biotech veteran Art Krieg explains the science behind his newest immunotherapy company, Zola Therapeutics, which uses both RNA and DNA agonists delivered in an LNP. Full video:
7:30

𝐓𝐡𝐞 𝐒𝐭𝐮𝐝𝐢𝐨 𝐚𝐭 𝐊𝐞𝐧𝐝𝐚𝐥𝐥 𝐒𝐪𝐮𝐚𝐫𝐞: Biotech veteran Art Krieg explains the science behind his newest immunotherapy company, Zola Therapeutics, which uses both RNA and DNA agonists delivered in an LNP. Full video:

BiotechTV

11,800 views • 1 year ago

𝐎𝐟𝐟-𝐓𝐚𝐫𝐠𝐞𝐭 𝐄𝐟𝐟𝐞𝐜𝐭𝐬: Perceptive Advisors' Joe Edelman discusses with Roivant Sciences CEO Matt Gline how biotech investing has changed over his extensive career, and his philosophy on running an investment firm. Watch the full episode:
3:18

𝐎𝐟𝐟-𝐓𝐚𝐫𝐠𝐞𝐭 𝐄𝐟𝐟𝐞𝐜𝐭𝐬: Perceptive Advisors' Joe Edelman discusses with Roivant Sciences CEO Matt Gline how biotech investing has changed over his extensive career, and his philosophy on running an investment firm. Watch the full episode:

BiotechTV

17,172 views • 2 months ago

𝐅𝐫𝐨𝐦 𝐒𝐞𝐨𝐮𝐥: Daejeon based Orum Therapeutics is pioneering the field of degrader-antibody conjugates. Founder SJ Lee describes the science and gives us an overview of biotech in Korea. Full video:
4:12

𝐅𝐫𝐨𝐦 𝐒𝐞𝐨𝐮𝐥: Daejeon based Orum Therapeutics is pioneering the field of degrader-antibody conjugates. Founder SJ Lee describes the science and gives us an overview of biotech in Korea. Full video:

BiotechTV

15,588 views • 1 year ago

𝐍𝐞𝐰 𝐒𝐡𝐨𝐰 𝐀𝐧𝐧𝐨𝐮𝐧𝐜𝐞𝐦𝐞𝐧𝐭: Today BiotechTV is excited to announce our newest regular show - Off-Target Effects with Matt Gline. Matt will share his perspective on news, and interview other biotech leaders. Visit the show's dedicated page:
2:56

𝐍𝐞𝐰 𝐒𝐡𝐨𝐰 𝐀𝐧𝐧𝐨𝐮𝐧𝐜𝐞𝐦𝐞𝐧𝐭: Today BiotechTV is excited to announce our newest regular show - Off-Target Effects with Matt Gline. Matt will share his perspective on news, and interview other biotech leaders. Visit the show's dedicated page:

BiotechTV

37,153 views • 1 year ago

𝐀𝐒𝐇 𝟐𝟎𝟐𝟓: Corvus CEO Richard Miller believes that ITK inhibitors can have the same broad impact on T-cell diseases as BTK inhibitors have had on B-cell diseases - he would know. $CRVS Full video:
3:33

𝐀𝐒𝐇 𝟐𝟎𝟐𝟓: Corvus CEO Richard Miller believes that ITK inhibitors can have the same broad impact on T-cell diseases as BTK inhibitors have had on B-cell diseases - he would know. $CRVS Full video:

BiotechTV

17,673 views • 8 months ago

𝐅𝐫𝐨𝐦 𝐍𝐘𝐒𝐄: AstraZeneca's CEO Pascal Soriot shares his take on M&A, oncology, Baxfendy for hypertension, the obesity market, and more. $AZN Full video:
4:58

𝐅𝐫𝐨𝐦 𝐍𝐘𝐒𝐄: AstraZeneca's CEO Pascal Soriot shares his take on M&A, oncology, Baxfendy for hypertension, the obesity market, and more. $AZN Full video:

BiotechTV

36,428 views • 2 months ago